HERVolution Therapeutics is attending the 2026 SENESCENCE2030 International Symposium in Naples on 8–9 September to discuss cellular senescence and its role in metabolic disease.
Public source
Publisher name
Public post
This week's #SENESCENCE2030 International Symposium in Naples asks how cellular senescence drives metabolic disease, from mechanism to clinical consequence. Our CSO, Pet…
Company
HERVolution Therapeutics
Dark Genome-Derived Therapeutics Targeting Cellular Senescence in Cancer & Metabolic Disease
- Industry
- Biotechnology Research
- Location
- Frederiksberg, DK
- Company size
- 11–50 employees
About HERVolution Therapeutics
Advancing immunotherapies targeting “dark genome” antigens, specifically HERV-K. Aberrant activation and expression of HERV-K in chronic inflammation, metabolic stress, cancer, and aging — drive immune evasion, senescence, and metabolic dysfunction and disease. By breaking immune tolerance to HERV-K, HERVolution is developing differentiated, off-the-shelf therapies that sit at the intersection of inflammation, type-2 diabetes disease, oncology, and longevity.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
GemPharmatech
GemPharmatech is hosting an annual symposium focused on metabolic disease in San Diego on September 11, 2026, featuring a program exploring obesity, insulin resistance, and cardiometabolic dysfunction.
Presence & Recognition
Nucleome Therapeutics
Nucleome Therapeutics is attending the From the Laboratory to the Clinic 2026 conference hosted by the University of Oxford's Kennedy Institute of Rheumatology in Oxford.
Presence & Recognition
Virion Therapeutics, LLC
Virion Therapeutics, LLC is presenting at the Science of HBV Cure and International Coalition in HBV Cure Research (ICE-HBV) meetings in Singapore.
Presence & Recognition
Cell and Gene Therapy Catapult
Cell and Gene Therapy Catapult is attending the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa in less than a month.
Presence & Recognition
Pluristyx, Inc.